IP Library Granted Patent US 9,783,792
Granted Patent B2
US 9,783,792 · App. 12/617,578 · Granted Oct 10, 2017

Purification of butyrylcholinesterase using membrane adsorption

Inventors: Alexander Zaydenberg (Woodland Hills, CA); Susan Weber (Los Angeles, CA); Patrick Gavit (Covina, CA); Laura Lei (Los Angeles, CA); Wolfgang Teschner (Vienna, AT); Harald A. Butterweck (Vienna, AT); Ursula Mais-Paul (Vienna, AT); Hans-Peter Schwarz (Vienna, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12N9/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,783,792
App. No.
12/617,578
Granted
Oct 10, 2017
Kind
B2
Abstract

The present invention relates to purification of butyrylcholinesterase using anion exchange material, where the butyrylcholinesterase content is enriched at least 10 fold per total protein in the composition.

Claims (21)

1. A method for making an enriched butyrylcholinesterase composition from a biological fluid having butyrylcholinesterase, the method comprising the steps of:

(A) contacting a biological fluid having butyrylcholinesterase with a fumed silica compound;

(B) adjusting the pH of the biological fluid contacted with the fumed silica compound in step (A) to a pH of from 4.15 to 4.35;

(C) filtering the pH adjusted biological fluid from step (B) to remove the fumed silica compound;

(D) applying the filtered biological fluid having butyrylcholinesterase from step (C) to a quaternary amine anion exchange material attached to a membrane equilibrated in with a buffer comprising acetate at a pH of from 4.15 to 4.35;

(E) washing the anion exchange material with a wash buffer comprising acetate;

(F) eluting butyrylcholinesterase from the anion exchange material by step elution with an elution buffer comprising acetate, thereby forming an enriched butyrylcholinesterase composition, wherein the butyrylcholinesterase content of the enriched butyrylcholinesterase composition is enriched at least 10 fold as compared to the starting biological fluid, as measured by butyrylcholinesterase activity per total protein; and

(G) enriching butyrylcholinesterase eluted from the anion exchange material in step (F) using a procainamide affinity purification material,

wherein the biological fluid in step (A) is a suspended Cohn Fraction IV.

2. The method of claim 1 , further comprising solvent-detergent treatment of the filtered biological fluid having butyrylcholinesterase from step (C), prior to step (D).

3. The method of claim 1 , wherein the total protein applied to the anion exchange membrane is at least 1000 mg per mL membrane volume.

4. The method of claim 1 , wherein the total protein applied to the anion exchange membrane is at least 2000 mg per mL membrane volume.

5. The method of claim 1 , wherein the butyrylcholinesterase content of the enriched butyrylcholinesterase composition is enriched at least 20 fold as compared to the starting biological fluid, as measured by butyrylcholinesterase activity per total protein.

6. The method of claim 1 , wherein the butyrylcholinesterase content of the enriched butyrylcholinesterase composition is enriched at least 40 fold as compared to the starting biological fluid, as measured by butyrylcholinesterase activity per total protein.

7. The method of claim 1 , wherein the butyrylcholinesterase content of the enriched butyrylcholinesterase composition is enriched at least 60 fold as compared to the starting biological fluid, as measured by butyrylcholinesterase activity per total protein.

8. The method of claim 1 , butyrylcholinesterase is applied to the anion exchange material attached to a membrane at a flow rate of at least 1.5 times membrane volume per minute.

9. The method of claim 1 , wherein the conductivity of the biological fluid applied to the anion exchange material attached to a membrane is 2.8 mS/cm or less.

10. The method of claim 1 , wherein the anion exchange material attached to a membrane is a Q membrane, and at least two Q membranes are connected in series.

11. The method of claim 1 , wherein the conductivity of the wash buffer in the washing step is 3.8 mS/cm or less.

12. The method of claim 1 , wherein the conductivity of the elution buffer in the eluting step is at least 5.6 mS/cm.

13. The method of claim 1 , wherein the membrane is in a series of two or more membranes.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2017
From: MAIS-PAUL, URSULA; SCHWARZ, HANS-PETER
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 043250/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036376/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036372/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2011
From: ZAYDENBERG, ALEXANDER; WEBER, SUSAN; GAVIT, PATRICK; LEI, LAURA; TESCHNER, WOLFGANG; BUTTERWECK, HARALD A.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 026505/0129 →
Continuity (2)
Provisional Application 61113899 · Nov 12, 2008
Related Publication 20100226907A1 · Sep 9, 2010